Accelrys Posts 3-Percent Rise in Q3 Revenue; Eyes 'Right M&A Opportunities' | GenomeWeb

Accelrys this week reported that third-quarter revenues rose 5 percent as a loss in the prior-year quarter swung to a profit, and a senior official said the company continues to eye "the right M&A opportunities."

Interim CEO Todd Johnson told investors during the firm's earnings conference call this week that he is "pleased" with the company's "rock-solid financials," and said the firm expects to add to its headcount during the year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.